Natalizumab Subcutaneous Immunogenicity and Safety Study
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the immunogenicity of natalizumab
(BG00002) 300 mg subcutaneous (SC) administered to participants with relapsing multiple
sclerosis (RMS). The secondary objectives of the study are to evaluate the safety of
natalizumab SC injections and to evaluate the efficacy of natalizumab SC injections on
relapses and on new magnetic resonance imaging (MRI) lesions.